Connect with our team to learn how we would tackle your target!
Our discovery workflows combine next-generation sequencing with proprietary bioinformatics to interrogate immune repertoires at depth, uncovering sequence and epitopic diversity that is often missed by traditional screening approaches. This data-driven strategy enables rapid generation of rich repertoires of potential leads while preserving a broad view of the immune landscape.
By learning directly from the natural immune response, this approach enables fast identification of lead panels with precision, taking advantage of in vivo selection to surface antibodies with favorable epitope coverage, affinity maturation, and intrinsic developability properties. Leads are selected with careful consideration of target biology and alignment to the intended target product profile.
We apply rational, sequence- and structure-informed humanization and engineering strategies tailored specifically for VHHs, optimizing candidates for downstream development while preserving affinity, specificity, and functional activity. Our approach balances framework selection, targeted modifications, and developability considerations to maintain the integrity of the original immune-derived response. Engineering decisions are guided by target biology, mechanism of action, and the intended target product profile, ensuring VHH candidates are well positioned for translation beyond discovery.
Beyond humanization, we support advanced VHH engineering, including bispecific and multispecific formats, affinity and avidity optimization, and sequence refinement to tune stability, expression, and functional performance while maintaining alignment with program objectives.
Have some upcoming VHH work? Reach out to us to see how we can help advance your project!